Economic Evaluation of Vancomycin Therapeutic Drug Monitoring Methods

• Status: Active, not recruiting
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Vancomycin is a widely used antibiotic in the treatment of complicated gram positive infections. Approaches to vancomycin therapeutic drug monitioring (TDM) vary. This clinical trial aimed to compare the pharmacoeconomic outcomes between various vancomyicn TDM approaches.

Research questions: Which vancomycin therapeutic drug monitoring (TDM) approach is associated with superior economic outcomes?

-Objectives: In this proposed multicenter randomized controlled trial (RCT), we aim to compare the pharmacoeconomic outcomes of various vancomycin TDM approaches.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamad Medical Corporation
• Collaborator: Qatar University
• Treatments: Vancomycin

Criteria

Inclusion Criteria:

• adults at least 18 yrs who are hospitalized and initiated on IV vancomycin

Exclusion Criteria:

• renal instability

• immunosuppression;

• vancomycin allergy;

• history of recurrent peritonitis

• administration of < 4 doses of vancomycin

• pregnancy;

• hemoglobin < 8 g/dL.